Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRM-ACT: Etoposide + doxorubicin + cisplatin + mitotane vs streptozotocin + mitotane in advanced adrenocortical carcinoma
2005-004137-18Phase 3Completed
- Sponsor
- Collaborative Group for Adrenocortical Carcinoma Treatment
- Start
- Jul 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of etoposide, doxorubicin, cisplatin, streptozocin and mitotane in adrenal cancer (ACC) (2 arms), sponsored by Collaborative Group for Adrenocortical Carcinoma Treatment. Primary endpoint: Overall survival. Started Jul 2006; status: completed.
02
Drugs
etoposidedoxorubicincisplatinstreptozocinmitotane
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2005-004137-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004137-18.